Evidence map›Paper›PMID 31601145›Full record

ArticleSmall GTPases2021

Fgd5 is a Rac1-specific Rho GEF that is selectively inhibited by aurintricarboxylic acid.

Sally Park, Yitian Guo, Judeah Negre, Jordane Preto, Cameron C Smithers, Abul Kalam Azad, Michael Overduin, Allan G Murray, Gary Eitzen

Open access · bronzeAbstract read
In one paragraph

Article in Small GTPases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. A Neurotensin Brake on Exploratory Drive under Persistent Threat.bioRxiv : the preprint server for biology · 2026
    Article
  2. Ang-1 and VEGF: central regulators of angiogenesis.Molecular and cellular biochemistry · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Discovery ofMicroorganisms · 2021
    Article
  7. Article
  8. Review
  9. Targeting Rac and Cdc42 GEFs in Metastatic Cancer.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sally ParkDepartment of Cell Biology, University of Alberta , Edmonton, Alberta, Canada.
Yitian GuoDepartment of Medicine-Division of Pulmonary Medicine, University of Alberta , Edmonton, Alberta, Canada.
Judeah NegreDepartment of Cell Biology, University of Alberta , Edmonton, Alberta, Canada.
Jordane PretoDepartment of Medicine, University of Alberta , Edmonton, Alberta, Canada.ORCID 0000-0002-6041-4008
Cameron C SmithersDepartment of Biochemistry, University of Alberta , Edmonton, Alberta, Canada.
Abul Kalam AzadDepartment of Medicine, Division of Nephrology, University of Alberta , Edmonton, Alberta, Canada.
Michael OverduinDepartment of Biochemistry, University of Alberta , Edmonton, Alberta, Canada.
Allan G MurrayDepartment of Medicine, Division of Nephrology, University of Alberta , Edmonton, Alberta, Canada.
Gary EitzenDepartment of Cell Biology, University of Alberta , Edmonton, Alberta, Canada.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rho proteins are signalling molecules that control cellular dynamics, movement and morphological changes. They are activated by Rho guanine-nucleotide exchange factors (Rho GEFs) that transduce upstream signals into Rho-mediated activation of downstream processes. Fgd5 is a Rho GEF involved in angiogenesis and its target Rho protein for this process has been linked to Cdc42 activation. Here, we examined the function of purified Fgd5, specifically, which Rho proteins it activates and pinpoint the structural domains required for enzymatic activity. Using a GEF enzyme assay, we found that purified Fgd5 showed preferential activation of Rac1 and direct binding of Rac1 in pull-down and co-immunoprecipitation assays. Structural comparisons showed that the Fgd5 DH domain is highly similar to the Rac1 GEF, TrioN, supporting a role for Fgd5 as a Rac1 GEF. Compounds that bind to purified Fgd5 DH-PH protein were identified by screening a small molecule library via surface plasmon resonance. The effects of eleven ligands were further examined for their ability to inhibit the Fgd5 GEF enzymatic activity and Rac1 interaction. From these studies, we found that the compound aurintricarboxylic acid, and to a lesser extent mitoxantrone dihydrochloride, inhibited both Fgd5 GEF activation of Rac1 and their interaction. Aurintricarboxylic acid had no effect on the activity or binding of the Rac1 GEF, TrioN, thus demonstrating the feasibility of selectively disrupting Rho GEF activators.

Indexed as

Aurintricarboxylic AcidGuanine Nucleotide Exchange Factorsrac1 GTP-Binding ProteinHumansProtein BindingRho Guanine Nucleotide Exchange FactorsAurintricarboxylic AcidFGD5 protein, humanGuanine Nucleotide Exchange Factorsrac1 GTP-Binding ProteinRAC1 protein, humanRho Guanine Nucleotide Exchange Factorsaurintricarboxylic acidguanine-nucleotide exchange factorRac1Rho GTPasesurface plasmon resonance

Identifiers

PMID31601145
PMCPMC7849785
OpenAlexW2979352001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.